00:52 , Mar 7, 2019 |  BioCentury  |  Regulation

Gottlieb’s durable reforms

While most of the changes Scott Gottlieb has set in motion in just under two years as FDA commissioner are works in progress, and some may falter in his absence, an important number are well...
18:23 , May 25, 2018 |  BC Week In Review  |  Clinical News

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and...
15:04 , May 18, 2018 |  BC Extra  |  Clinical News

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and...
23:58 , Apr 19, 2018 |  BC Innovations  |  Product R&D

Automation navigation

Last year’s approvals of the first two CAR T therapies have prompted the field to get serious about industrializing manufacturing of the cells to improve reproducibility and lower costs. While stakeholders agree that automation will...
00:54 , Mar 10, 2018 |  BioCentury  |  Product Development

Defining progress

Erleada apalutamide’s landmark approval established a new primary endpoint in prostate cancer that shortens the time it takes to run the trials by up to five years, and paves the way for treating disease before...
00:59 , Sep 2, 2017 |  BioCentury  |  Strategy

Pathfinding for access

A pact with the Centers for Medicare & Medicaid Services for Novartis AG ’s CAR T therapy demonstrates leadership in new value-based drug pricing models. Kymriah tisagenlecleucel represents a milestone for three reasons. Its approval...
18:45 , Jul 6, 2017 |  BC Week In Review  |  Company News

Sanpower completes acquisition of Dendreon from Valeant

Sanpower Group Co. Ltd. (Nanjing, China) completed the purchase of Dendreon Pharmaceuticals Inc. from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) for $819.9 million in cash. In February 2015, Valeant acquired bankrupt Dendreon's assets, including global...
23:15 , Jun 30, 2017 |  BC Extra  |  Company News

Sanpower completes Dendreon acquisition

Sanpower Group Co. Ltd. (Nanjing, China) said it completed the purchase of Dendreon Pharmaceuticals Inc. from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) for $819.9 million in cash. In February 2015, Valeant acquired bankrupt Dendreon's assets,...
20:57 , Jun 1, 2017 |  BC Week In Review  |  Clinical News

NewLink reports Phase II data for indoximod following Provenge in CRPC

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, NewLink Genetics Corp. (NASDAQ:NLNK) reported data from 35 evaluable patients with metastatic castration-resistant prostate cancer (CRPC) in a Phase II...
22:27 , Mar 16, 2017 |  BC Innovations  |  Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...